Advertisement Covers CROI 2017


Incidence of All Cancers but Lung Cancer Drops After HIV Group Stops Smoking

March 7, 2017

Incidence of all cancers combined fell in the years after HIV-positive people stopped smoking, according to results of a nine-year 35,424-person analysis. The exception was lung cancer, which remained at high incidence in quitters compared with never-smokers through more than five years after smoking stopped.

Non-AIDS cancers emerged as a major cause of morbidity and mortality in HIV populations after the introduction of potent antiretroviral therapy. Smoking, which contributes to development of lung cancer and several other malignancies, remains highly prevalent in people with HIV. In the United States, for example, the Centers for Disease Control and Prevention estimates that 42% of HIV-positive people smoke, compared with 21% of the general population. Researchers working with the D:A:D cohorts conducted this study to assess the impact of stopping smoking on incidence of lung cancer and other cancers.

D:A:D is an ongoing observational study of HIV cohorts in Europe, the United States and Australia. The smoking analysis included all cohort members without a cancer history. Follow-up began when a person entered D:A:D or January 2004 and continued to a first cancer diagnosis, death, the last study visit plus six months or February 2015. The investigators divided participants into current smokers, never-smokers, ex-smokers at baseline and smokers who stopped smoking during follow-up. The last group included five subgroups: those who had stopped smoking for less than one year, for one to two years, for two to three years, for three to five years or for more than five years. The D:A:D team used Poisson regression analysis to assess the impact of stopping smoking on incidence of (1) all cancers combined, (2) smoking-unrelated cancers, (3) smoking-related cancers excluding lung cancer and (4) lung cancer.

Related: New HIV Capsid Inhibitor Strongly Stops HIV Replication at Two Steps

The study group included 35,424 HIV-positive people, 72.5% of them men. At baseline, 53% had a viral load below 500 copies/mL, median CD4 count measured 444 cells/mm3 and median age stood at 40 years (interquartile range 34 to 46). Through a median follow-up of nine years, 1,980 cancers developed, including 1,251 smoking-unrelated cancers, 487 smoking-related cancers excluding lung cancer and 242 lung cancers.

Compared with people who never smoked, in people who quit incidence of all cancers was highest within the first year of quitting (adjusted rate ratio about 1.6), then fell significantly (P for trend < .01) to match the incidence in never-smokers after smokers had quit more than five years. The same type of analysis confirmed significant declines in relative incidence of smoking-unrelated cancers from less than one year after quitting to more than five years (P for trend = 0.04) and of smoking-related cancers excluding lung cancer (P for trend = .04). But lung cancer incidence remained elevated compared with never-smokers, standing more than 11 times higher within the first year of quitting and remaining about eight times higher among people who had quit more than five years (P for trend = .13).

The D:A:D investigators propose that persistently elevated lung cancer incidence after smoking stops in this HIV cohort "suggests that the oncogenic potential for smoking is not reversed for lung cancer in the time frame that we have investigated." They add that lung cancer incidence in HIV-negative people does drop consistently with longer time since quitting. While discouraging HIV-positive people from starting smoking and promoting cessation remain priorities, the researchers stress that "monitoring and awareness of lung cancer should continue in those who stop smoking." They advocate longer studies of HIV-positive people who quit smoking to learn "whether and when lung cancer incidence declines."

Mark Mascolini writes about HIV infection.

Related Stories

IL-1β Inhibitor Lowers Arterial Inflammation in Adults With Controlled HIV
Classic Risk Factors Drive Heart Attack Rates More Than HIV Variables
HIV Vaccine Induces Sustained HIV Remission in Proof-of-Concept Study

This article was provided by TheBodyPRO. It is a part of the publication The 24th Conference on Retroviruses and Opportunistic Infections.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.